Compare Stitch Fix Inc (SFIX) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Stitch Fix Inc vs 10X Genomics Inc — how do they compare? Stitch Fix Inc trades at $3.79 (market cap $530.37M), while 10X Genomics Inc trades at $58.51 (market cap $7.64B). The key difference: 10X Genomics Inc is far larger — about 14.4× Stitch Fix Inc's market cap, and 10X Genomics Inc is trading nearer its 52-week high, Stitch Fix Inc nearer its low. Which is the better fit depends on your goals.
| SFIX | TXG | |
|---|---|---|
Market Cap | $530.37M | $7.64B |
Sector | Consumer Cyclical | Health |
52-Week High | $5.83 | $58.57 |
52-Week Low | $3.06 | $11.34 |
Enterprise Value | $418.08M | $7.17B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Stitch Fix (SFIX) trades at $4.20, up 4.22% today, showing stabilization after a multi-year decline. The stock is technically bullish with strong moving average signals, while fundamentals reflect a turnaround with revenue stabilizing at $1.27B and net losses narrowing to -$28.74M in 2025. Recent news highlights AI-driven personalization gains and a debt-free balance sheet, supporting a potential recovery narrative.
The outlook hinges on execution of the turnaround; improving client growth and cost controls offer upside, but persistent losses and consumer spending pressures pose risks. Analysts are cautious with a $4.75 price target and 63.6% hold rating, suggesting the stock may be fairly valued amid its recovery phase.
TXG is trading at $52.03, up 14.1% in the past 24 hours, reflecting strong momentum. The stock exhibits a bullish technical signal with moving averages supporting upward trends, while RSI levels suggest mild overbought conditions. Fundamentally, the company reported Q2 2026 revenue of $151 million, beating estimates, and has shown consistent earnings beats in recent quarters. Recent news highlights collaborations with Cleveland Clinic and the acquisition of Proteintech Genomics, expanding its multiomics capabilities and reinforcing growth prospects.
The outlook for TXG is cautiously optimistic, driven by earnings outperformance and strategic expansions, but risks include persistent net losses and high valuation multiples. Analyst consensus is mixed with a $46 price target, indicating potential downside from current levels. Investors should weigh revenue growth against profitability challenges and monitor execution on new initiatives for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Stitch Fix Inc
Stitch Fix Inc offers personal style service for men and women. The company engages in delivering one-to-one personalization to clients through the combination of data science and human judgment. It provides a shipment service called A FIX where the stylist's hand selects items from several merchandises with analysis of client and merchandise data to provide a personalized shipment of apparel, shoes, and accessories suited to the client's needs. The company offers products across categories, brands, product types and price points including Women's, Petite, Maternity, Men's and Plus. It also offers various product types, including denim, dresses, blouses, skirts, shoes, jewelry and handbags, and sells merchandise across various range of price points.
Read more on SFIX →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
